Research & Education

ELCC 2016: Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy

April 15, 2016

ELCC 2016
                                                                                                                         Media contact                                          
                                                                                                                         ELCC Press Office                    
                                                                                                                         E-mail media@esmo.org      

 

Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy

GENEVA, Switzerland, 15 April 2016 – Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

The randomised phase III SQUIRE trial demonstrated that the addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival in patients with stage IV squamous non-small-cell lung cancer by 1.6 months compared to chemotherapy alone. The current study analysed outcomes in the subgroup of patients with EGFR expressing tumours  compared to those with no EGFRs.

Out of 982 patients in the SQUIRE trial, 95% had EGFR expressing tumours and 5% had tumours with no EGFR protein. The addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival and progression free survival by 21% and 16%, respectively, as compared to chemotherapy alone in patients whose tumours expressed the EGFR protein. There was no benefit in patients with no EGFR in their tumours.

Dr Luis Paz-Ares, Chief of medical oncology at the University Hospital 12 De Octubre in Madrid, Spain, lead author, said: “Necitumumab is targeted at EGFR so it makes sense that the drug is active in patients with the receptor. Our analysis showed that the drug had no effect when the receptor was absent, presumably because there was no target to bind to. We cannot make robust conclusions because the subgroup of patients with negative EGFR was very small, but the hypothesis generated here is that those tumours do not respond well to necitumumab.”

“Based on this analysis, the European Medicines Agency has decided that necitumumab is approved only for patients with EGFR expressing tumours,” continued Paz-Ares. “On the other hand the US Food and Drug Administration has taken the more conservative approach which recognises that SQUIRE was designed for all-comers without prior selection, and this subgroup analysis is insufficient evidence to conclude that patients with EGFR negative tumours are not candidates.”

He concluded: “Our results need to be interpreted with caution. A confirmatory study in patients with EGFR negative tumours is needed to assess whether they are good candidates for necitumumab or not.”

Commenting on the findings, Prof Robert Pirker, programme director for lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the study, said: “This subgroup analysis shows that the effect of necitumumab was slightly greater in patients with EGFR expressing tumours than it was in the entire SQUIRE population. It indicates that immunohistochemical detection of the EGFR receptor improves clinical activity of necitumumab. The findings are consistent with previous studies suggesting that monoclonal antibodies in combination with chemotherapy work better in patients with EGFR expressing cells.”

Pirker added that a more thorough analysis is needed. He said: “Information on outcome of patients with cut- off levels higher than in the current analysis would be of interest. We also need to know the effect of necitumumab according to both percentages of positive cells and their staining intensity. This could be combined with fluorescence in situ hybridisation (FISH) analysis to detect gene amplification. This could give us a clearer picture of which patients benefit most from necitumumab.”

References

1 132O_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first- line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). L. Paz-Ares, Spain. Friday 15th April 2016 – 09:00-09:15 NSCLC targeted therapy and circulating biomarkers Room C

Notes to Editors
Disclaimer

Information contained in this press release was provided by the lecture authors. It does not necessarily express ESMO's or IASLC’s point of view.

 

About ELCC 2016
The European Lung Cancer Conference (ELCC) has become the reference event in Europe for professionals treating lung cancers. It is organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), in collaboration with the partner societies ESTRO, ESTS and ETOP. ELCC provides a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2,000 attendees are expected from throughout Europe and the rest of the world.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.

About ESMO
ESMO is the leading professional organization for medical oncology. With more than 14,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. ESMO’s educational resources support an integrated, multi-professional approach to cancer care. With European roots and a global reach, ESMO welcomes oncology professionals from around the world and seeks to erase boundaries in cancer care while pursuing its mission across oncology, worldwide. To learn more, visit www.esmo.org.

ELCC Partners

 

###